Fusen Pharmaceutical Co. Ltd. (1652.HK) announced Monday that Compound Potassium Hydrogen Phosphate Injection developed by its unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited has received approval from China's National Medical Products Administration as a phosphate supplement.
The company noted that Compound Potassium Hydrogen Phosphate Injection, Shanweixi, is primarily used as a parenteral nutrition supplement and to treat hypophosphatemia in adult and pediatric patients when oral or enteral supplements are not feasible, insufficient, or contraindicated.
The injection is a Class B drug under the National Healthcare Security Administration. It scientifically calibrates between monopotassium and dipotassium phosphate in order to rapidly treat phosphorus deficiency as a new-generation phosphorus-potassium compound formula. The characteristics of the drug include high safety, rapid onset, dual supplementation of phosphate and potassium, and multi-guideline consensus.
The simultaneous potassium supplement helps stabilize membrane potential, and prevent the risk of rhabdomyolysis and arrhythmia induced by hypophosphatemia.
According to China Medical and Pharmaceutical Economic Information Network, the sales of Compound Potassium Hydrogen Phosphate Injection in China were RMB343 million and RMB413 million in 2023 and 2024, respectively.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.